EVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evaxion A/S is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock lacks a strong technical breakout, has no proprietary buy signal today, and the latest quarter showed weak profitability with declining cash and equity. Analyst coverage is still positive overall, but the recent price target cuts and the company’s ongoing cash burn make this more of a speculative biotech name than a suitable immediate long-term purchase. For an impatient investor who wants to deploy capital now, this is a hold rather than a buy.
EVAX is trading near 4.06, slightly below the pivot at 4.332 and just above support at 4.018. The MACD histogram is negative and still expanding lower, which indicates weakening momentum. RSI_6 at 32.7 is near oversold but not yet a strong reversal signal. Moving averages are converging, suggesting a lack of trend conviction. Overall, the chart shows a weak and uncertain near-term setup rather than a clear bullish entry.
Recent analyst coverage remains constructive, with Lake Street maintaining a Buy rating despite lowering its target to $9, JonesResearch initiating with a Buy and $10 target, and Maxim also starting coverage at Buy with a $10 target. The company’s AI-driven platform and its melanoma asset are being viewed as potentially strategically interesting. Similar candlestick pattern analysis suggests only modest upside over the next week and month, but not a strong immediate catalyst.
The latest Q1 2026 report showed GAAP EPS of -$0.01 and a steep drop in financial income to $0.3 million from $2.4 million year over year. Cash and cash equivalents fell to $18.4 million from $23.2 million at year-end 2025, and total equity declined to $13.2 million from $17.0 million. Revenue in the prior 2025/Q4 snapshot dropped to zero, highlighting an unreliable operating base. No recent insider, hedge fund, or congress trading support is present. AI Stock Picker and SwingMax both show no signal today.
In Q1 2026, Evaxion posted GAAP EPS of -$0.01, indicating continued losses. The latest available quarterly snapshot from 2025/Q4 shows revenue fell to 0, down 100% YoY, while net income remained deeply negative at -$5.918 million. EPS was also negative at -$0.01. The main trend is not growth but continued dependence on financing and limited operating revenue generation.
Analyst sentiment is still moderately positive, but less aggressive than before. Lake Street cut its price target to $9 from $11 while keeping Buy, JonesResearch initiated Buy with a $10 target, and Maxim also initiated Buy at $10. The Wall Street view is therefore bullish on the story and platform, but the lowered target from Lake Street shows some caution. Overall, pros see strategic upside and potential licensing value, while the cons side is the weak financial profile and cash burn.
